Notice Pursuant to the National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc.

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

September 16, 2026

Issuing agencies

Justice DepartmentAntitrust Division

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 178 (Wednesday, September 16, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 178 (Wednesday, September 16, 2026)]
[Notices]
[Pages 58708-58709]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-19004]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Subcutaneous Drug Development & Delivery 
Consortium, Inc.

    Notice is hereby given that, on January 12, 2026, pursuant to 
section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug 
Development & Delivery Consortium, Inc.

[[Page 58709]]

(``Subcutaneous Drug Development & Delivery Consortium, Inc.'') has 
filed written notifications simultaneously with the Attorney General 
and the Federal Trade Commission disclosing changes in its membership. 
The notifications were filed for the purpose of extending the Act's 
provisions limiting the recovery of antitrust plaintiffs to actual 
damages under specified circumstances. Specifically, Novo Nordisk, 
Bagsvaerd, KINGDOM OF DENMARK, has withdrawn as a party to this 
venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and Subcutaneous Drug Development & 
Delivery Consortium, Inc. intends to file additional written 
notifications disclosing all changes in membership.
    On October 26, 2020, Subcutaneous Drug Development & Delivery 
Consortium, Inc. filed its original notification pursuant to section 
6(a) of the Act. The Department of Justice published a notice in the 
Federal Register pursuant to section 6(b) of the Act on December 3, 
2020 (85 FR 78148).
    The last notification was filed with the Department on May 23, 
2025. A notice was published in the Federal Register pursuant to 
section 6(b) of the Act on June 13, 2025 (90 FR 25081).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2026-19004 Filed 9-15-26; 8:45 am]
BILLING CODE P


</pre></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on September 16, 2026.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.